Assistive technology, decoded for clinicians.
A clinician-first guide to evaluating, prescribing, and implementing assistive technology — from AI hearing aids and AAC tablets to exoskeletons and smart prosthetics. What's changed in the last 12 months, what insurance actually pays for, and how to pick the right device without abandoning the patient mid-trial.
Why AT is having a moment
Three forces converged in 2024–2026. AI moved core AT functions — captioning, image description, AAC prediction — from "useful" to "clinical-grade." Regulation opened OTC hearing aids and expanded CMS coverage for speech-generating devices and powered mobility. And consumer hardware (Apple, Meta, Google) baked accessibility features into mainstream phones, watches, and glasses — collapsing prices and stigma. The result: more of your patients can benefit from AT now than at any point in the last decade.
The five AT categories you'll actually prescribe
Examples: Smart power wheelchairs, robotic exoskeletons (Ekso, ReWalk), powered orthotics, gait-training robotics
2026 trend: Exoskeletons crossed into outpatient rehab in 2025. FDA-cleared devices now reimbursable under L-codes for SCI and stroke rehab.
Examples: Tobii Dynavox, Proloquo2Go, eye-gaze tablets, AI-predictive text systems
2026 trend: LLM-powered AAC predicts full sentences from a single symbol. Voice-banking is now offered routinely at ALS diagnosis.
Examples: OTC hearing aids with AI noise separation, smart glasses for low vision (eSight, OrCam), live captioning
2026 trend: OTC hearing-aid rule (2022) collapsed prices; FDA-cleared AI hearing aids now match prescription devices on speech-in-noise.
Examples: Reminder/scheduling apps, AI executive-function coaches, smart pill dispensers, dementia wayfinding tools
2026 trend: Prescription Digital Therapeutics (PDTs) for ADHD and cognitive rehab are growing, but reimbursement remains the bottleneck.
Examples: Myoelectric/bionic prosthetics, robotic feeders (Obi), smart-home automation for SCI patients
2026 trend: Pattern-recognition control reduces prosthetic abandonment. Voice-controlled smart-home stacks are now standard SCI-discharge planning.
The 60% abandonment problem
Across categories, roughly 30–60% of prescribed AT devices are abandoned within a year. The drivers are well-documented: poor fit to real-world environment, inadequate training, no follow-up, and the patient not being part of the device selection. The single biggest predictor of long-term use is whether the patient trialed the device in their actual home or workplace before the prescription was finalized.
Evaluating a device: the practical checklist
- Define the functional goal first, not the device. "Communicate with grandchildren on video calls" is a goal; "AAC tablet" is one of several solutions.
- Use SETT or HAAT. Map the patient, environment, tasks, and tool options before narrowing. Skipping this step is how people end up with $8K wheelchairs that don't fit through the bathroom door.
- Confirm regulatory status. FDA-cleared, FDA-registered, or consumer product? It changes liability, reimbursement, and what claims you can make in the chart.
- Verify coverage upfront. Pull the HCPCS / CPT codes, pre-auth requirements, and the patient's plan-specific DME benefits before the trial.
- Trial in context. Two weeks minimum in the real environment. In-clinic-only trials produce abandonment data, not adoption.
- Train the caregiver, not just the patient. 80% of long-term success depends on the person who'll troubleshoot at 9pm on a Sunday.
- Schedule the 90-day follow-up at prescription. If you don't book it now, it won't happen — and that's when small fit issues become permanent non-adherence.
What's new in 2026
- AI live-captioning is accurate enough for medical encounters in English and Spanish. Several health systems are issuing captioning-enabled badges to clinicians for use with deaf and hard-of-hearing patients.
- Smart-glass low-vision aids (OrCam MyEye, Envision Glasses, Meta Ray-Ban with Be My Eyes) now read text, recognize faces, and describe scenes in real time. Several states cover them through vocational rehab, even when private insurance does not.
- LLM-powered AAC (Proloquo, Lingraphica, TouchChat) reduces keystrokes for non-verbal patients by 60–80% — the largest single improvement in AAC since symbol-based systems.
- Exoskeletons in outpatient rehab. ReWalk and Ekso are now billable under specific L-codes for SCI and post-stroke gait training; sessions average $250–$400.
- BCIs in trial. Synchron, Neuralink, and Precision Neuroscience have implanted devices in patients with ALS and high-cervical SCI. Don't promise this to patients yet, but expect referrals to research sites to increase.
What this means for medtech teams
If you're building AT, three things decide whether clinicians will prescribe what you've built: (1) a clear regulatory and reimbursement path mapped to existing HCPCS/CPT codes, (2) an evaluation kit clinicians can use in a single visit, and (3) caregiver training built into the product, not bolted on. The companies winning this cycle pair an AI capability with a billing and training motion clinicians already recognize.
FAQ
What counts as assistive technology in a clinical setting?
Assistive technology (AT) is any device, software, or system that helps a person perform a task they otherwise couldn't — or makes it safer or easier. In clinical practice this spans mobility (smart wheelchairs, exoskeletons), communication (AAC tablets, eye-gaze), sensory (hearing aids with AI noise separation, screen readers), cognitive (reminder apps, AI scheduling), and ADL aids (smart prosthetics, robotic feeders).
Is assistive technology covered by Medicare?
Many durable medical equipment (DME) categories are covered — manual and power wheelchairs, speech-generating devices (E2500–E2511), CPAPs, prosthetics — when medical necessity is documented. Coverage gaps remain for many consumer-grade AI aids (smart glasses, AAC apps on personal tablets), though that's shifting as CMS expands remote-care and DME categories.
How do I evaluate an AT device before prescribing it?
Use a structured framework like SETT (Student/patient, Environment, Tasks, Tools) or HAAT (Human, Activity, Assistive Technology, Context). Trial the device in the patient's real environment, not just the clinic. Confirm FDA status for medical-device claims, check insurance coverage codes upfront, and document the functional goal the device addresses.
What's the difference between AT and accessibility software?
Accessibility features (built-in screen readers, voice control) are general-purpose and free in most operating systems. Assistive technology is purpose-built for a specific functional limitation and often requires clinical prescription, training, or customization. The line is blurring fast as iOS and Android ship clinical-grade AT features.
How is AI changing assistive technology?
AI is the single biggest shift in AT in a decade. Real-time captioning is now accurate enough for clinical communication. AI image-description (Be My Eyes + GPT-4o, Seeing AI) replaces what used to require a human aide. Predictive AAC reduces keystrokes for non-verbal patients by 60–80%. Brain-computer interfaces are entering clinical trials for ALS and high-cervical SCI. Expect CMS coverage debates to intensify through 2026–2027.
Who pays for assistive technology evaluation visits?
Occupational therapy and speech-language pathology evaluations for AT are billable under standard OT/SLP CPT codes (97165–97168 for OT eval, 92607–92608 for AAC eval). PT can bill AT-related codes for mobility devices. Wheelchair seating evaluations have dedicated codes (97542, 97755). Always verify with the patient's plan — some require pre-authorization.
Smillin is the daily 5-minute brief on AI, devices, and digital tools for clinicians — including assistive-technology updates, FDA clearances, and coverage changes as CMS rolls them out. Subscribe free →